These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 12438534)

  • 21. Comparative antiplatelet efficacy of a novel, nonpeptide GPIIb/IIIa antagonist (XV454) and abciximab (c7E3) in flow models of thrombosis.
    Abulencia JP; Tien N; McCarty OJ; Plymire D; Mousa SA; Konstantopoulos K
    Arterioscler Thromb Vasc Biol; 2001 Jan; 21(1):149-56. PubMed ID: 11145947
    [TBL] [Abstract][Full Text] [Related]  

  • 22. In vitro measurement of platelet glycoprotein IIb/IIIa receptor blockade by abciximab: interindividual variation and increased platelet secretion.
    Rossi F; Rossi E; Pareti FI; Colli S; Tremoli E; Gallo L
    Haematologica; 2001 Feb; 86(2):192-8. PubMed ID: 11224490
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Testing platelet activation with a shear-dependent platelet function test versus aggregation-based tests: relevance for monitoring long-term glycoprotein IIb/IIIa inhibition.
    Osende JI; Fuster V; Lev EI; Shimbo D; Rauch U; Marmur JD; Richard M; Varon D; Badimon JJ
    Circulation; 2001 Mar; 103(11):1488-91. PubMed ID: 11257073
    [TBL] [Abstract][Full Text] [Related]  

  • 24. P2Y12 receptor blockade augments glycoprotein IIb-IIIa antagonist inhibition of platelet activation, aggregation, and procoagulant activity.
    Berny-Lang MA; Jakubowski JA; Sugidachi A; Barnard MR; Michelson AD; Frelinger AL
    J Am Heart Assoc; 2013 May; 2(3):e000026. PubMed ID: 23676293
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Incomplete inhibition of platelet aggregation and glycoprotein IIb-IIIa receptor blockade by abciximab: importance of internal pool of glycoprotein IIb-IIIa receptors.
    Gawaz M; Ruf A; Pogatsa-Murray G; Dickfeld T; Rüdiger S; Taubitz W; Fischer J; Müller I; Meier D; Patscheke H; Schömig A
    Thromb Haemost; 2000 Jun; 83(6):915-22. PubMed ID: 10896249
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Ability of anti-glycoprotein IIb/IIIa agents to dissolve platelet thrombi formed on a collagen surface under blood flow conditions.
    Goto S; Tamura N; Ishida H
    J Am Coll Cardiol; 2004 Jul; 44(2):316-23. PubMed ID: 15261925
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Platelet microparticle formation and thrombin generation under high shear are effectively suppressed by a monoclonal antibody against GPIba.
    Pontiggia L; Steiner B; Ulrichts H; Deckmyn H; Forestier M; Beer JH
    Thromb Haemost; 2006 Dec; 96(6):774-80. PubMed ID: 17139372
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Upregulation of GP IIb/IIIa receptors during platelet activation: influence on efficacy of receptor blockade.
    Matzdorff A; Voss R
    Thromb Res; 2006; 117(3):307-14. PubMed ID: 15894353
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Ability of different glycoprotein IIb-IIIa ligands to support platelet aggregation induced by activating antibody CRC54.
    Naimushin YA; Mazurov AV
    Biochemistry (Mosc); 2005 Jul; 70(7):782-9. PubMed ID: 16097942
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Induction of fibrinogen binding and platelet aggregation as a potential intrinsic property of various glycoprotein IIb/IIIa (alphaIIbbeta3) inhibitors.
    Peter K; Schwarz M; Ylänne J; Kohler B; Moser M; Nordt T; Salbach P; Kübler W; Bode C
    Blood; 1998 Nov; 92(9):3240-9. PubMed ID: 9787160
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Variable inhibition of high-shear-induced platelet plug formation by eptifibatide and tirofiban under conditions of platelet activation and high von Willebrand release: a randomized, placebo-controlled, clinical trial.
    Derhaschnig U; Pachinger C; Jilma B
    Am Heart J; 2004 Apr; 147(4):E17. PubMed ID: 15077100
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The in-vitro effect of tirofiban, glycoprotein IIb/IIIa antagonist, on various responses of porcine blood platelets.
    Ciborowski M; Tomasiak M; Rusak T; Winnicka K; Dobrzycki S
    Blood Coagul Fibrinolysis; 2008 Sep; 19(6):557-67. PubMed ID: 18685439
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of the glycoprotein IIb/IIIa antagonist Roxifiban on P-selectin expression, fibrinogen binding, and microaggregate formation in a phase I dose-finding study: no evidence for platelet activation during treatment with a glycoprotein IIb/IIIa antagonist.
    Seiffert D; Thomas BE; Bradley JD; Munzer DA; Tchinnes MA; Kornhauser DM; Cain VA; Hua TA; Feuerstein GZ; Martin DE; Stern AM
    Platelets; 2003 May; 14(3):179-87. PubMed ID: 12850842
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Desmopressin antagonizes the in vitro platelet dysfunction induced by GPIIb/IIIa inhibitors and aspirin.
    Reiter RA; Mayr F; Blazicek H; Galehr E; Jilma-Stohlawetz P; Domanovits H; Jilma B
    Blood; 2003 Dec; 102(13):4594-9. PubMed ID: 12920042
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparative real-time effects on platelet adhesion and aggregation under flowing conditions of in vivo aspirin, heparin, and monoclonal antibody fragment against glycoprotein IIb-IIIa.
    Turner NA; Moake JL; Kamat SG; Schafer AI; Kleiman NS; Jordan R; McIntire LV
    Circulation; 1995 Mar; 91(5):1354-62. PubMed ID: 7867173
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Low incidence of paradoxical platelet activation by glycoprotein IIb/IIIa inhibitors.
    Weber AA; Meila D; Jacobs C; Weber S; Kelm M; Strauer BE; Zotz RB; Scharf RE; Schrör K
    Thromb Res; 2002 Apr; 106(1):25-9. PubMed ID: 12165285
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Platelet GPIIb/IIIa binding characteristics of small molecule RGD mimetic: distinct binding profile for Roxifiban.
    Mousa SA; Bozarth JM; Naik UP; Slee A
    Br J Pharmacol; 2001 Jun; 133(3):331-6. PubMed ID: 11375248
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacology of the intravenous platelet receptor glycoprotein IIb-IIIa antagonists.
    Kleiman NS
    Coron Artery Dis; 1998; 9(9):603-16. PubMed ID: 9861523
    [No Abstract]   [Full Text] [Related]  

  • 39. Abciximab, eptifibatide, and tirofiban exhibit dose-dependent potencies to dissolve platelet aggregates.
    Moser M; Bertram U; Peter K; Bode C; Ruef J
    J Cardiovasc Pharmacol; 2003 Apr; 41(4):586-92. PubMed ID: 12658060
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacologic platelet anesthesia by glycoprotein IIb/IIIa complex antagonist and argatroban during in vitro extracorporeal circulation.
    Kanemitsu S; Nishikawa M; Onoda K; Shimono T; Shimpo H; Yazaki A; Tanaka K; Shiku H; Yada I
    J Thorac Cardiovasc Surg; 2003 Aug; 126(2):428-35. PubMed ID: 12928640
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.